| Aug 14 |
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Aug 13 |
Top Midday Decliners
|
| Aug 13 |
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
|
| Aug 13 |
Syros’ stock craters after Phase II AML trial termination due to inefficacy
|
| Aug 12 |
Syros ending enrollment in phase 2 leukemia study
|
| Aug 12 |
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
|
| Aug 5 |
Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?
|
| Jul 31 |
Syros Pharmaceuticals, Inc. (SYRS) Q2 2024 Earnings Call Transcript
|
| Jul 31 |
Syros Pharmaceuticals GAAP EPS of -$0.59 beats by $0.18
|
| Jul 31 |
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
|
